Cold plasma cancer cell therapy exploits this mechanism by driving ROS to trigger cleavage of Hsp90 chaperones and degradation of PKD2, which further stabilizes HIF-1α and activates NF-κB and VEGFA, and subsequent tissue vascularization to promote tumor angiogenesis.62, 63, 64 This reveals that despite targeting the same protein, distinct mechanisms govern cancerous cell progression. The gene discussed is HIF1A; the disease is neoplasm.